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 Chapter 5
Circulating miRNAs in the diagnosis of 
HFpEF versus HFrEF
hFpeF versus hFreF: 
Can microRNAs advance the diagnosis?
European Journal of Heart Failure 2015 Apr;17(4):351-4
Daniela Schmitter
Adriaan A. Voors
Pim van der Harst
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this editorial refers to “Circulating microRNAs in heart failure with reduced and 
preserved left ventricular ejection fraction”, by l. wong et al. and „microRNA sig-
natures differentiate preserved from reduced ejection fraction heart failure“, by 
C.J. watson et al., published in this issue, European Journal of Heart Failure (2015); 
17: 393–415.
Although Heart Failure with preserved Ejection fraction (HFpEF) and Heart Failure with 
reduced Ejection Fraction (HFrEF) have similar morbidity and mortality risks, both types 
of heart failure (HF) require specific disease management due to their distinctly differ-
ent pathophysiology. In addition, the diagnosis of HFpEF requires additional and often 
complex evidence for a functional or structural cardiac abnormality, together with a 
preserved left ventricular ejection fraction. This makes the diagnosis of HFpEF complex. 
Therefore, tools to improve the diagnosis and prognostication of HFpEF are of great 
interest and are key towards targeted treatment.1-2
MicroRNAs (miRNAs) are conserved small non-coding RNA molecules (21-25 nucleo-
tides in length) that regulate gene expression by base-pairing to the complementary 
mRNA sequences resulting in translational repression or messenger RNA degradation.3 
(Figure 1) MiRNAs are implicated in cardiac development and have been linked to the 
pathogenesis of a plethora of diseases and conditions, including HF.4-5 The exact down-
stream molecular mechanisms by which miRNAs could influence disease development 
and progression are poorly understood. The current and ongoing research efforts sug-
gest added value of miRNAs as diagnostic and prognostic tools for HF.6-8
Wong et al.9 and Watson10 et al. studied the role of miRNAs to improve the diagnosis 
of HF and to differentiate between HFpEF and HFrEF. Wong et al. identified 12 miRNAs 
that significantly differed between HF and non-HF controls. Four of these (miR-125a-5p, 
miR-550a-5p, miR-190a, miR-638) could differentiate patients with HFpEF versus HFrEF. 
The AUC values of individual miRNAs had a lower discriminative power in HFpEF versus 
HFrEF than NT-proBNP, but the miRNA panel in combination with NT-proBNP achieved 
maximal diagnostic accuracy (AUC 1.0; Table 1). Similarly, Watson et al. discovered five 
circulating miRNA candidates (miR-375, miR-146a, miR-30c, miR-328, miR-221) all with 
reduced levels in HF patients and able to distinguish HFpEF from HFrEF with a diag-
nostic potential that was superior for miR-375 and two miRNA combinations compared 
to log(BNP). And again, highest intergroup distinction was achieved by combining the 
miRNA panel with log(BNP) (AUC 0.86; Table 1).
Both studies align in presenting promising data supporting added value of miRNAs in 
diagnosing HF and in distinguishing HFpEF from HFrEF. Interestingly, except for miR-221, 
there was no overlap in the identified miRNAs between both studies. However, while 
Watson et al. found miR-221 to differentiate HFpEF from HFrEF, miR-221 was only able 
to distinguish between HF and control patients in the study of Wong et al. In addition, 
116 Chapter 5
the current two studies did not show any overlap with the miRNAs identified but not 
validated in the earlier work of Ellis et.al (Table 1).11
The lack of overlap is intriguing. There are several potential explanations. Firstly, 
major variances in methodology. Differences in sample collection and preparation 
may influence the results. Wong et al. performed miRNA profiling in whole blood and 
corresponding plasma samples but did not determine which sample type is more ap-
propriate for circulating miRNA detection and quantification. Each study used different 
methods for detecting miRNAs. Microarrays have been widely and extensively used as 
an efficient method for circulating miRNA profiling. Although considered less sensitive 
than quantitative reverse transcription polymerase chain reaction (qPCR) quantification, 
microarray analysis is an essential tool for the discovery phase, while qPCR is the gold 
standard for miRNA quantification and validation of microarray data. An important 
difference of the Watson study is the analysis of pooled samples with only one array 
readout per cohort during the discovery phase. Differential levels of some miRNAs may 
not have been detected by screening a pool and outliers could impact the generated 
data. Quantitative PCR validation in an independent cohort would have strengthened 
the findings. Furthermore, the low amount of total RNA in blood demands for a precise 
normalization of the detected miRNAs. Any pre-analytical variations such as sample 
storage, degree of hemolysis and extraction efficiency could affect miRNA normaliza-
tion and quantification. Additional methods could be employed, including spiking-in 
oligonucleotides, standardization against stably detectable miRNAs and/or the mean of 
all measured miRNAs to validate the results further.
Secondly, more large scale studies with well-defined control, external validation 
cohorts and cohorts with non-cardiac conditions e.g. including for example dyspnoeic/ 
breathlessness COPD patients are required in order to further understand these findings 
and to limit the noise caused by different heart failure etiologies, concomitant diseases 
and treatments. The results of both studies presented in this issue require further ex-
ternal validation in larger independent cohorts to assess the utility of the discovered 
circulating miRNA biomarker candidates.
Finally, when interpreting the data confounders such as medication and common 
cardiovascular risk factors, such as diabetes, hypertension and BMI, must be considered.
With our current knowledge about circulating miRNAs and the variability of the 
available research results in HF, how can we clinically use miRNAs in the future? With 
the advances in technology it soon will become feasible to measure a large number of 
biomarkers including miRNAs simultaneously in blood samples at relatively low costs. 
The development of next- and third generation sequencing technologies offers an in-
creasingly efficient alternative for the discovery of novel or low-expressed miRNAs and 
will overcome the limitations of array and PCR based technologies.12
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In line with advances in technology, further “harmonization” of data and analyses, 
including the isolation and handling of clinical samples, normalization methods and 
analytical standards will improve inter-study comparability. This will also allow cross-
referencing and large scale global collaborations in a variety of cohorts.
To support the exciting hypothesis of a causal role of miRNAs, Wong et al. performed a 
pathway analysis based on the identified HFpEF and HFrEF specific miRNAs. Differences 
of miRNA levels could be linked to several pathways of potential relevance in the HF 
disease process such as neurotrophin and Wnt signaling as well as p53 signaling. The 
identification of regulatory and disease specific miRNAs that do not only mark but also 
have a causal association with HF might provide a foundation for targeted therapeutic 
table 1. Circulating micro RNAs as potential diagnostic markers to differentiate heart failure with preserved 



















miR-125a-5p 0.61 0.91 √ √ √ √ X
Wong
et. al [9]
miR-190a 0.66 0.91 √ √ √ √ X
miR-550a-5p 0.58 0.79 √ √ √ √ X
miR-638 0.60 0.86 √ √ √ √ X
miRNA panel 0.80 1.00 √ √ √ √ X
NTproBNP 0.83 √ √ √ √ X
(miRNA + Log(BNP))
miR-30c 0.52 0.67 √ √ X
Watson
et. al [10]
miR-146a 0.57 0.69 √ √ X
miR-221 0.64 0.72 √ √ X
miR-328 0.66 0.77 √ √ X
miR-375 0.75 0.78 √ √ X
all miRNA panel 0.80 0.86 √ √ X
Log(BNP) 0.66 √ √ X
miR-342-3p
no values for comparison




miR-199a-3p √ √ X
miR-150 √ √ X
miR-29a √ √ X
miR-2110 √ √ X
miR-27b √ √ X
miR-940 √ √ X
miR-23a √ √ X
AUC, area under the curve; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with 
reduced ejection fraction; miRNA, micro RNA; qPCR; quantitative reverse transcription–PCR.
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approaches and personalized medicine (Figure 1). In theory, miRNAs can be targeted in 
vivo by using synthetic molecules (anti-miRs and miRNA mimics) that result in changes 
of expression of the messenger-RNA and hence influence entire signaling pathways.13 
Currently, the field of miRNA research in HF is only in its infancy but it is surrounded by 
exciting data and novel hypotheses that might, eventually, lead to improvements in the 
diagnosis, prognostication and personalized treatment of HF.
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Figure 1. Micro RNA (miRNA) mechanism and potential clinical application of disease-specific miRNAs. 
miRNAs target complementary sequences within mRNA molecules leading to gene silencing and reduced/
blocked protein expression. Circulating miRNAs that are specifically associated with a certain type of dis-
ease or condition such as heart failure with preserved ejection fraction (HFpEF) and heart failure with re-
duced ejection fraction (HFrEF) are evaluated as novel diagnostic and prognostic biomarkers and could 
become potential targets for therapeutic applications. UTR, untranslated region.
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